Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 1, 2022Circulation Heart FailureOpen Access

Rationale and Design of the Cardiac CARE Trial: A Randomized Trial of Troponin-Guided Neurohormonal Blockade for the Prevention of Anthracycline Cardiotoxicity

View Full Paper
Ask AI
Bookmark
Share

Key result

Cardiac CARE trial evaluates troponin-guided candesartan and carvedilol to prevent LV dysfunction following anthracycline therapy.

Why the study?

Anthracyclines cause cardiotoxicity and heart failure with variable severity and no proven therapeutic intervention, while neurohormonal blockade has shown modest cardioprotective effects in unselected patients.

Does troponin-guided treatment with combination candesartan and carvedilol prevent the development of left ventricular dysfunction in high-risk patients receiving anthracycline chemotherapy?

Population

Patients with breast cancer and non-Hodgkin lymphoma receiving anthracycline chemotherapy with high-sensitivity cTnI in the upper tertile

Comparison

Standard of care plus candesartan and carvedilol vs standard of care alone

Design

Multicentre prospective randomized open-label blinded end point trial

Follow-up

6 months after chemotherapy

Authors

PHPeter HenriksenInterventional CardiologyPHPeter HallRutgers, The State University of New JerseyOOOlga OikonomidouEdinburgh Cancer Research

Discussion

Loading...

Member takes

Implication

May support selective cardioprotection with beta blockers or RAS inhibitors in anthracycline recipients; leaves open whether RCTs will confirm benefit.

Study Design

Type

RCT

Blinding

Open-label, blinded endpoint (PROBE)

Randomization

1:1

Multicenter

Yes

Structured PICO

Does troponin-guided treatment with combination candesartan and carvedilol prevent the development of left ventricular dysfunction in high-risk patients receiving anthracycline chemotherapy?

P
Population
Patients with breast cancer and non-Hodgkin lymphoma receiving anthracycline chemotherapy who have elevated high-sensitivity cardiac troponin I concentrations, followed for 6 months.
I
Intervention
Combination candesartan and carvedilol therapy added to standard of care
C
Comparator
Standard of care alone
O
Outcome
Change in left ventricular ejection fraction at 6 months after chemotherapy measured by cardiac magnetic resonance imagingsurrogate

The Cardiac CARE trial is designed to evaluate whether troponin-guided neurohormonal blockade with candesartan and carvedilol can prevent left ventricular dysfunction in high-risk patients receiving anthracycline chemotherapy.

Cite This Study

Henriksen et al. (2022) conducted an RCT in Breast cancer and non-Hodgkin lymphoma receiving anthracycline chemotherapy. Candesartan and carvedilol vs. Standard of care alone was evaluated on Change in left ventricular ejection fraction at 6 months after chemotherapy. The Cardiac CARE trial is a rationale and design study evaluating whether troponin-guided treatment with candesartan and carvedilol prevents left ventricular dysfunction following anthracycline therapy.

synapsesocial.com/papers/6aa52a9289092379003a49d0https://doi.org/10.1161/circheartfailure.121.009445

Topics

HFrEF treatmentHeart failureCardio-oncology
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Effect of Enalapril on Mortality and the Development of Heart Failure in Asymptomatic Patients with Reduced Left Ventricular Ejection Fractions1992 · 3,758 citations
  2. 2Sequential Treatment Assignment with Balancing for Prognostic Factors in the Controlled Clinical Trial1975 · 2,393 citations
  3. 3Carvedilol for Prevention of Chemotherapy-Related Cardiotoxicity2018 · 512 citations
  4. 4Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 × 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol2016 · 697 citations
  5. 5Quantitative Evaluation of Drug or Device Effects on Ventricular Remodeling as Predictors of Therapeutic Effects on Mortality in Patients With Heart Failure and Reduced Ejection Fraction2010 · 496 citations